Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MANBA | O00462 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | IDUA | P35475 | 1/20 | 0.56 |
| ▸ | GUSB | P08236 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14391479 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL16687559 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL12216738 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL25070350 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL19638526 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL23111379 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL8079451 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL23532013 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL1893475 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL17017514 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371244-A1 | METHOD FOR TREATING PROSTATE CANCER BY USE OF PHARMACEUTICAL COMPOSITION CONTAINING A3 ADENOSINE RECEPTOR AGONIST | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-12-18 | — | — | US | disclosed |
| US-20120322815-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A3 ADENOSINE RECEPTOR AGONIST | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-12-20 | — | — | US | disclosed |
| US-7199127-B2 | Purine nucleosides | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371244-A1 | METHOD FOR TREATING PROSTATE CANCER BY USE OF PHARMACEUTICAL COMPOSITION CONTAINING A3 ADENOSINE RECEPTOR AGONIST | ADORA3, ADORA2A, ADORA2B | LMNA 2693/4885HIF1A 3565/4885MANBA 2671/4885 |
| US-20120322815-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A3 ADENOSINE RECEPTOR AGONIST | ADORA3, ADORA2A, ADORA1 | LMNA 3154/4885HIF1A 3211/4885MANBA 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.